The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01X | Other antineoplastic agents | |
| 4 | L01XK | Poly (ADP-ribose) polymerase (PARP) inhibitors | |
| 5 | L01XK01 |
| Active Ingredient | Description | |
|---|---|---|
| Olaparib |
Olaparib is a potent inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2 and PARP-3), and has been shown to inhibit the growth of selected tumour cell lines in vitro and tumour growth in vivo either as a standalone treatment or in combination with established chemotherapies. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| LYNPARZA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| LYNPARZA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
